1243 related articles for article (PubMed ID: 11602509)
21. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
22. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
23. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brosen K
Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
[TBL] [Abstract][Full Text] [Related]
24. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
25. In vitro effects of tacrolimus on human cytochrome P450.
Lecointre K; Furlan V; Taburet AM
Fundam Clin Pharmacol; 2002 Dec; 16(6):455-60. PubMed ID: 12685503
[TBL] [Abstract][Full Text] [Related]
26. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
28. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
29. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
Or PM; Lam FF; Kwan YW; Cho CH; Lau CP; Yu H; Lin G; Lau CB; Fung KP; Leung PC; Yeung JH
Phytomedicine; 2012 Apr; 19(6):535-44. PubMed ID: 22261394
[TBL] [Abstract][Full Text] [Related]
30. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
31. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
[TBL] [Abstract][Full Text] [Related]
32. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
33. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
34. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
35. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
36. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
37. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
Barecki ME; Casciano CN; Johnson WW; Clement RP
Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723
[TBL] [Abstract][Full Text] [Related]
39. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
40. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
